Results 161 to 170 of about 236,396 (261)

Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression. [PDF]

Curr Oncol
Svarna A, Liontos M, Goula K, Pardali K, Koutsoumpogeras K, Aravantinou K, Perdikari KC, Kollarou I, Kaparelou M, Haidopoulos D, Dimitrakakis C, Dimopoulos MA, Zagouri F.   +12 more
europepmc   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Progress of estrogen receptor and spliceosome in endometrial carcinoma. [PDF]

Front Endocrinol (Lausanne)
Hong Z, Mo T, Zhou P, Chen J, Li X.
europepmc   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer. [PDF]

J Clin Oncol
Freeman JQ, Nanda R, Howard FM.
europepmc   +1 more source

Estrogen Receptors

Journal of Biological Chemistry, 1971
George Giannopoulos, Jack Gorski
openaire   +1 more source

Genetic regulation of the estrogen receptor and inherited predisposition to breast cancer. [PDF]

Proc Natl Acad Sci U S A
Pierce SB, Kortbawi H, Gulsuner S, Mandell JB, Lee MK, Walsh T, King MC.   +6 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances. [PDF]

Int J Mol Sci
Huang Z, Wu Y, Li Y.
europepmc   +1 more source

Estrogen receptor [PDF]

Science-Business eXchange, 2009
openaire   +1 more source